Matches in SemOpenAlex for { <https://semopenalex.org/work/W3121107908> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W3121107908 endingPage "S27" @default.
- W3121107908 startingPage "S26" @default.
- W3121107908 abstract "Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor (a TGF-β “trap”) fused to a human IgG1 mAb blocking PD-L1. Results from a global phase 1 study (NCT02517398) found an objective response rate (ORR) of 27.5%, median overall survival (OS) of 17.1 months, and a manageable safety profile in patients who received bintrafusp alfa 1200 mg every 2 weeks (Q2W) in the 2L setting at 2 years of follow-up. Here we present efficacy and safety data for 3 years of follow up. Patients with advanced NSCLC, unselected for PD-L1 expression, who had disease progression after platinum-based 1L treatment with no prior immunotherapy were randomized to receive bintrafusp alfa at the recommended phase 2 dose of 1200 mg (n=40) Q2W until disease progression, unacceptable toxicity, or trial withdrawal. The primary objective was best overall response per RECIST 1.1. Secondary and exploratory objectives included safety, duration of response (DOR), and OS. As of March 31, 2020, 40 patients received bintrafusp alfa 1200 mg Q2W for a median of 16.9 (range, 2-160) weeks. The median follow-up was 153.3 weeks, and 16 patients were still alive; 2 patients had an ongoing response, and 1 patient remained on treatment. The median DOR was 18 months and 21.2% (n=2) of patients had responses lasting ≥24 months. The 12-, 24-, and 36-month OS rates were 66.2%, 39.7%, and 23.2%, respectively. By subgroups of PD-L1 expression, the median OS was 21.7 months in PD-L1 positive (≥1%) patients and not reached in patients with high PD-L1 expression (≥80% by 73-10 assay). The 36-month OS rate was 33.6% in PD-L1 positive patients and 66.7% in patients with high PD-L1 expression. No new safety signals were observed. After 3 years of follow-up, bintrafusp alfa at 1200 mg Q2W as 2L therapy continues to show durable responses and long-term survival with a manageable toxicity profile in patients with advanced NSCLC. A phase 3 study evaluating bintrafusp alfa vs pembrolizumab as 1L treatment for patients with advanced NSCLC with high PD-L1 expression is ongoing (NCT03631706). Previously presented at ESMO 2020, Abstract 1443, Paz-Ares L, et al. Reused with permission." @default.
- W3121107908 created "2021-01-18" @default.
- W3121107908 creator A5001638690 @default.
- W3121107908 creator A5009005412 @default.
- W3121107908 creator A5009502217 @default.
- W3121107908 creator A5013149755 @default.
- W3121107908 creator A5019254463 @default.
- W3121107908 creator A5020674154 @default.
- W3121107908 creator A5032175106 @default.
- W3121107908 creator A5043165289 @default.
- W3121107908 creator A5052765751 @default.
- W3121107908 creator A5066576514 @default.
- W3121107908 creator A5073896274 @default.
- W3121107908 creator A5075323885 @default.
- W3121107908 creator A5075417603 @default.
- W3121107908 creator A5090324173 @default.
- W3121107908 date "2021-01-01" @default.
- W3121107908 modified "2023-10-18" @default.
- W3121107908 title "MO01.27 Three-Year Follow-up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, as Second-Line (2L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)" @default.
- W3121107908 doi "https://doi.org/10.1016/j.jtho.2020.10.132" @default.
- W3121107908 hasPublicationYear "2021" @default.
- W3121107908 type Work @default.
- W3121107908 sameAs 3121107908 @default.
- W3121107908 citedByCount "0" @default.
- W3121107908 crossrefType "journal-article" @default.
- W3121107908 hasAuthorship W3121107908A5001638690 @default.
- W3121107908 hasAuthorship W3121107908A5009005412 @default.
- W3121107908 hasAuthorship W3121107908A5009502217 @default.
- W3121107908 hasAuthorship W3121107908A5013149755 @default.
- W3121107908 hasAuthorship W3121107908A5019254463 @default.
- W3121107908 hasAuthorship W3121107908A5020674154 @default.
- W3121107908 hasAuthorship W3121107908A5032175106 @default.
- W3121107908 hasAuthorship W3121107908A5043165289 @default.
- W3121107908 hasAuthorship W3121107908A5052765751 @default.
- W3121107908 hasAuthorship W3121107908A5066576514 @default.
- W3121107908 hasAuthorship W3121107908A5073896274 @default.
- W3121107908 hasAuthorship W3121107908A5075323885 @default.
- W3121107908 hasAuthorship W3121107908A5075417603 @default.
- W3121107908 hasAuthorship W3121107908A5090324173 @default.
- W3121107908 hasBestOaLocation W31211079081 @default.
- W3121107908 hasConcept C126322002 @default.
- W3121107908 hasConcept C141071460 @default.
- W3121107908 hasConcept C143998085 @default.
- W3121107908 hasConcept C197934379 @default.
- W3121107908 hasConcept C2776256026 @default.
- W3121107908 hasConcept C2779177807 @default.
- W3121107908 hasConcept C2779984678 @default.
- W3121107908 hasConcept C31760486 @default.
- W3121107908 hasConcept C535046627 @default.
- W3121107908 hasConcept C71924100 @default.
- W3121107908 hasConcept C81729549 @default.
- W3121107908 hasConcept C90924648 @default.
- W3121107908 hasConceptScore W3121107908C126322002 @default.
- W3121107908 hasConceptScore W3121107908C141071460 @default.
- W3121107908 hasConceptScore W3121107908C143998085 @default.
- W3121107908 hasConceptScore W3121107908C197934379 @default.
- W3121107908 hasConceptScore W3121107908C2776256026 @default.
- W3121107908 hasConceptScore W3121107908C2779177807 @default.
- W3121107908 hasConceptScore W3121107908C2779984678 @default.
- W3121107908 hasConceptScore W3121107908C31760486 @default.
- W3121107908 hasConceptScore W3121107908C535046627 @default.
- W3121107908 hasConceptScore W3121107908C71924100 @default.
- W3121107908 hasConceptScore W3121107908C81729549 @default.
- W3121107908 hasConceptScore W3121107908C90924648 @default.
- W3121107908 hasIssue "1" @default.
- W3121107908 hasLocation W31211079081 @default.
- W3121107908 hasOpenAccess W3121107908 @default.
- W3121107908 hasPrimaryLocation W31211079081 @default.
- W3121107908 hasRelatedWork W1964812149 @default.
- W3121107908 hasRelatedWork W2079526095 @default.
- W3121107908 hasRelatedWork W2085889668 @default.
- W3121107908 hasRelatedWork W2087468199 @default.
- W3121107908 hasRelatedWork W2389807988 @default.
- W3121107908 hasRelatedWork W2518309888 @default.
- W3121107908 hasRelatedWork W2980533584 @default.
- W3121107908 hasRelatedWork W3137800304 @default.
- W3121107908 hasRelatedWork W3202210589 @default.
- W3121107908 hasRelatedWork W4327944896 @default.
- W3121107908 hasVolume "16" @default.
- W3121107908 isParatext "false" @default.
- W3121107908 isRetracted "false" @default.
- W3121107908 magId "3121107908" @default.
- W3121107908 workType "article" @default.